Q8CGK5
Gene name |
Ifnlr1 (Il28ra) |
Protein name |
Interferon lambda receptor 1 |
Names |
IFN-lambda R1, Cytokine receptor class-II member 12, Cytokine receptor family 2 member 12, CRF2-12, Interleukin-28 receptor subunit alpha, IL-28 receptor subunit alpha, IL-28R-alpha, IL-28RA |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:242700 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
3 structures for Q8CGK5
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 7T6F | EM | 360 A | C/D | 249-298 | PDB |
| 8EWY | EM | 550 A | C/D | 249-298 | PDB |
| AF-Q8CGK5-F1 | Predicted | AlphaFoldDB |
27 variants for Q8CGK5
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs261762242 | 8 | A>V | No | EVA | |
| rs3388721648 | 64 | K>I | No | EVA | |
| rs3388715752 | 86 | L>R | No | EVA | |
| rs3388722106 | 92 | Y>* | No | EVA | |
| rs3388721698 | 108 | S>F | No | EVA | |
| rs3388722111 | 130 | V>E | No | EVA | |
| rs3388718058 | 197 | A>T | No | EVA | |
| rs3388722031 | 200 | V>A | No | EVA | |
| rs27601956 | 231 | M>L | No | EVA | |
| rs27601955 | 242 | V>I | No | EVA | |
| rs217456061 | 246 | V>A | No | EVA | |
| rs3388718121 | 274 | P>S | No | EVA | |
| rs3388716198 | 278 | F>L | No | EVA | |
| rs27601950 | 301 | N>T | No | EVA | |
| rs247058433 | 310 | P>S | No | EVA | |
| rs217620830 | 319 | R>K | No | EVA | |
| rs256904584 | 358 | S>L | No | EVA | |
| rs3388725489 | 364 | G>E | No | EVA | |
| rs3388727723 | 387 | D>E | No | EVA | |
| rs218066254 | 414 | D>E | No | EVA | |
| rs3388712714 | 417 | P>H | No | EVA | |
| rs3394650872 | 439 | E>G | No | EVA | |
| rs3388727720 | 442 | L>M | No | EVA | |
| rs27601946 | 448 | G>E | No | EVA | |
| rs3388715725 | 453 | G>A | No | EVA | |
| rs3394901630 | 484 | E>G | No | EVA | |
| rs578884178 | 487 | Q>E | No | EVA |
No associated diseases with Q8CGK5
1 regional properties for Q8CGK5
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Fibronectin type III | 10 - 121 | IPR003961 |
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| integral component of plasma membrane | The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| interleukin-28 receptor complex | A protein complex that binds interleukin-28 and interleukin-29. It is composed of an alpha and a beta receptor subunit (in human IFNLR1/IL28Ralpha & IL10RB) and either Interleukin-28 (IFNL2 or IFNL3) or Interleukin-29 (IFNL1). |
1 GO annotations of molecular function
| Name | Definition |
|---|---|
| cytokine receptor activity | Combining with a cytokine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
6 GO annotations of biological process
| Name | Definition |
|---|---|
| cytokine-mediated signaling pathway | The series of molecular signals initiated by the binding of a cytokine to a receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| defense response to virus | Reactions triggered in response to the presence of a virus that act to protect the cell or organism. |
| mucosal immune response | An immune response taking place in mucosal tissues, including those of the intestinal tract, nasal and upper respiratory tract, and genital tract. |
| positive regulation of cellular respiration | Any process that activates or increases the frequency, rate or extent of cellular respiration. |
| regulation of defense response to virus by host | Any host process that modulates the frequency, rate, or extent of the antiviral response of a host cell or organism. |
| response to type III interferon | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a type III interferon stimulus. Interferon lambda is the only member of the type III interferon found so far. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MWRADRWAPL | LLFLLQSALG | RPRLAPPRNV | TLFSQNFTVY | LTWLPGLGSP | PNVTYFVTYQ |
| 70 | 80 | 90 | 100 | 110 | 120 |
| SYIKTGWRPV | EHCAGIKALV | CPLMCLKKLN | LYSKFKGRVQ | AASAHGRSPR | VESRYLEYLF |
| 130 | 140 | 150 | 160 | 170 | 180 |
| DVELAPPTLV | LTQMEKILRV | NATYQLPPCM | PSLELKYQVE | FWKEGLGSKT | LFPDTPYGQP |
| 190 | 200 | 210 | 220 | 230 | 240 |
| VQIPLQQGAS | RRHCLSARTV | YTLIDIKYSQ | FSEPSCIFLE | APGDKRAVLA | MPSLLLLLIA |
| 250 | 260 | 270 | 280 | 290 | 300 |
| AVAAGVAWKI | MKGNPWFQGV | KTPRALDFSE | YRYPVATFQP | SGPEFSDDLI | LCPQKELTIR |
| 310 | 320 | 330 | 340 | 350 | 360 |
| NRPAPQVRNP | ATLQAGPERD | STEDEDEDTD | YDDDGDSVQP | YLERPLFISE | KPRVMEHSET |
| 370 | 380 | 390 | 400 | 410 | 420 |
| DESGVDSGGP | WTSPVGSDGS | SAWDSSDRSW | SSTGDSSYKD | EVGSSSCLDR | KEPDQAPCGD |
| 430 | 440 | 450 | 460 | 470 | 480 |
| WLQEALPCLE | FSEDLGTVEE | PLKDGLSGWR | ISGSLSSKRD | LAPVEPPVSL | QTLTFCWVNN |
| 490 | 500 | 510 | 520 | 530 | |
| PEGEEEQEDE | EEEEEEEEEE | DWESEPKGSN | AGCWGTSSVQ | RTEVRGRMLG | DYLVR |